XBiotech shares crater as CHMP shud­ders at its ap­pli­ca­tion to sell Xilonix

It’s pos­si­ble Austin-based XBiotech just doesn’t get it.

The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use — the CHMP — put to­geth­er an in­for­mal trend vote on the biotech’s ap­pli­ca­tion for Xilonix as a new drug for col­orec­tal can­cer, pro­vid­ing a hard sig­nal the for­mal vote will go against XBiotech af­ter con­clud­ing the biotech has no da­ta to prove that the drug works.

Like­ly out­come: out­right re­jec­tion. XBiotech’s shares cratered, drop­ping 35% on its lat­est set­back, which has been com­ing hard and fast.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER